{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T02:19:59Z","timestamp":1782267599529,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007311","name":"Cleveland Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007311","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.msard.2025.106675","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T07:36:37Z","timestamp":1755243397000},"page":"106675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Efficacy and safety of ocrelizumab in pediatric multiple sclerosis"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5187-8284","authenticated-orcid":false,"given":"Ahmad","family":"Altelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azza","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Mifsud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzi","family":"Elhabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luai","family":"Eldweik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutaz","family":"Atieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naji","family":"Riachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palat","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youstina","family":"Ghoris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Shatila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7530-6800","authenticated-orcid":false,"given":"Anu","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106675_bib0001","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1212\/WNL.0000000000202658","article-title":"Real-world effectiveness of ocrelizumab in a multi-centre Pediatric-Onset Multiple Sclerosis (POMS) cohort in the United Kingdom (S31.007)","volume":"100","author":"Abdel-Mannan","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106675_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106539","article-title":"Ocrelizumab for pediatric relapsing multiple sclerosis","volume":"100","author":"Alroughani","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106675_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2023.01.011","article-title":"Ocrelizumab in pediatric multiple sclerosis","volume":"43","author":"Amirov","year":"2023","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.msard.2025.106675_bib0004","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1001\/jamaneurol.2023.5566","article-title":"Highly effective therapies as first-line treatment for pediatric-onset multiple sclerosis","volume":"81","author":"Benallegue","year":"2024","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2025.106675_bib0005","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.msard.2013.06.004","article-title":"Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years","volume":"3","author":"Benson","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106675_bib0006","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16228","article-title":"Rituximab treatment in pediatric-onset multiple sclerosis","volume":"31","author":"Breu","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106675_bib0007","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16228","article-title":"Rituximab treatment in pediatric-onset multiple sclerosis","volume":"31","author":"Breu","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106675_bib0008","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1177\/1352458520949986","article-title":"Adverse event profile differences between rituximab and ocrelizumab: findings from the FDA adverse event reporting database","volume":"27","author":"Caldito","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106675_bib0010","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.pediatrneurol.2025.03.008","article-title":"Dimethyl fumarate for pediatric-onset multiple sclerosis: a systematic review","volume":"167","author":"Etemadifar","year":"2025","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.msard.2025.106675_bib0011","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(20)30432-4","article-title":"Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care","volume":"20","author":"Fadda","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106675_bib0012","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/PHMT.S220817","article-title":"Review of the safety, efficacy and tolerability of fingolimod in the treatment of pediatric patients with Relapsing-Remitting Forms of Multiple Sclerosis (RRMS)","volume":"10","author":"Feng","year":"2019","journal-title":"Pediatric. Health Med. Ther."},{"key":"10.1016\/j.msard.2025.106675_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105703","article-title":"Disease modifying treatment guidelines for multiple sclerosis in the United Arab Emirates","volume":"88","author":"Jacob","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106675_bib0014","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1177\/0883073819845827","article-title":"Epidemiology of pediatric-onset multiple sclerosis: a systematic review of the literature","volume":"34","author":"Jeong","year":"2019","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.msard.2025.106675_bib0015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00415-024-12879-z","article-title":"Ocrelizumab dose selection for treatment of pediatric relapsing\u2013remitting multiple sclerosis: results of the OPERETTA I study","volume":"272","author":"Mar","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106675_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105647","article-title":"Clinical and magnetic resonance imaging outcomes in pediatric-onset MS patients on fingolimod and ocrelizumab","volume":"87","author":"Nasr","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106675_bib0017","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40272-021-00471-1","article-title":"Teriflunomide: pediatric first approval","volume":"23","author":"Paik","year":"2021","journal-title":"Pediatr. Drugs"},{"key":"10.1016\/j.msard.2025.106675_bib0018","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa067597","article-title":"Natural history of multiple sclerosis with childhood onset","volume":"356","author":"Renoux","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106675_bib0019","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamaneurol.2023.1625","article-title":"Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis","volume":"80","author":"Roos","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2025.106675_bib0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pediatrneurol.2023.04.020","article-title":"Demographic features and clinical course of patients with pediatric-onset multiple sclerosis on newer disease-modifying treatments","volume":"145","author":"Shukla","year":"2023","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.msard.2025.106675_bib0021","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208114","article-title":"Comparative effectiveness of natalizumab, fingolimod, and injectable therapies in pediatric-onset multiple sclerosis","volume":"102","author":"Spelman","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106675_bib0022","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pediatrneurol.2024.12.015","article-title":"Safety and efficacy of fingolimod and ocrelizumab in pediatric patients with multiple sclerosis","volume":"164","author":"Spirek","year":"2025","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.msard.2025.106675_bib0023","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/13524585231223069","article-title":"Control of disease activity with large extended-interval dosing of rituximab\/ocrelizumab in highly active pediatric multiple sclerosis","volume":"30","author":"Venet","year":"2024","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106675_bib0009","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"Von","year":"2007","journal-title":"The Lancet"},{"key":"10.1016\/j.msard.2025.106675_bib0024","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1212\/WNL.0000000000003028","article-title":"Pediatric multiple sclerosis","volume":"87","author":"Waldman","year":"2016","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T23:16:52Z","timestamp":1774999012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825004171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":24,"alternative-id":["S2211034825004171"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106675","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of ocrelizumab in pediatric multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106675","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106675"}}